Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naoky Tsai

Gastroenterology Kailua, HI Medical Doctor

NPI 1245214618 CMS profile 147004

642 Ulukahiki St, Ste 103, Kailua, HI 96734

Open in the dashboard

General payments

$587,378

966 records reported · program years 2019–2025

Research payments

$94,690

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naoky Tsai of Kailua, HI is reported in the CMS Open Payments database as having received $587,378 across 966 general payments and $94,690 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $155,198 207
2025 Research $55,250 5
2024 General $102,973 169
2024 Research $39,440 12
2023 General $72,806 140
2022 General $108,342 164
2021 General $20,760 62
2020 General $59,446 86
2019 General $67,852 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naoky Tsai
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Naoky Tsai were reported at $155,198. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Naoky Tsai Gastroenterology median Middle half National median
2019 $67,852 $417 $126–$1,100 $163
2020 $59,446 $224 $74–$624 $114
2021 $20,760 $352 $106–$1,054 $132
2022 $108,342 $448 $129–$1,270 $149
2023 $72,806 $533 $150–$1,390 $160
2024 $102,973 $605 $160–$1,606 $164
2025 $155,198 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $261,725 416 payments
  2. Madrigal Pharmaceuticals $130,308 117 payments
  3. AbbVie, Inc. $81,471 157 payments
  4. Intercept Pharmaceuticals, Inc. $68,360 65 payments
  5. Ipsen Biopharmaceuticals, Inc $33,367 23 payments
  6. Novo Nordisk Inc $2,786 8 payments
  7. E.R. Squibb & Sons, L.L.C. $2,403 50 payments
  8. Echosens North America, Inc. $1,549 3 payments
  9. Janssen Biotech, Inc. $936 28 payments
  10. Exact Sciences Corporation $757 9 payments
  11. Other $3,716 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $357,588 114 payments
  2. Travel and Lodging $124,784 174 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $38,920 16 payments
  4. Food and Beverage $34,472 638 payments
  5. Consulting Fee $19,809 7 payments
  6. Honoraria $11,550 10 payments
  7. Education $255 7 payments
Products named General payments · program years 2019–2025
  1. Vemlidy $113,685 92 payments
  2. REZDIFFRA Liver Disease $98,210 83 payments
  3. Epclusa $87,473 82 payments
  4. MAVYRET $72,342 135 payments
  5. OCALIVA Hepatology / Gastroenterology $60,739 49 payments
  6. IQIRVO $33,227 22 payments
  7. REZDIFFRA Liver Disease $31,396 25 payments
  8. Livdelzi $26,619 28 payments
  9. OCALIVA Hepatology Gastroenterology $7,490 15 payments
  10. OPDIVO $1,614 44 payments
  11. Other $7,817 160 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bausch Health US, LLC $94,690 17 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

447

Median for Gastroenterology: 569

Drug cost

$439,505

Median for Gastroenterology: $104,976

Branded share of claims

26.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entecavir Generic 139 $147,253
Vemlidy Tenofovir Alafenamide Brand 86 $145,537
Rezdiffra Resmetirom Brand 17 $67,793
Xifaxan Rifaximin Brand 15 $53,940
Ursodiol Generic 73 $13,588
Tenofovir Disoproxil Fumarate Generic 25 $8,791
Omeprazole Generic 50 $1,423
Sucralfate Generic 15 $1,077
Prednisone Generic 27 $103

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$40,479

Medicare's payments for the services billed

Medicare patients

202

Average age 74

Services billed

417

134 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 41%
Chronic kidney disease 28%
Osteoporosis 28%
Ischemic heart disease 27%
Cancer 18%
COPD 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REZDIFFRA
$31,396 17 —
Vemlidy
$18,108 86 —
Livdelzi
$13,116 — —
OCALIVA
$8,682 — —
Epclusa
$8,436 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

983 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record